Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in YouthRajen Mody, Arul M. Chinnaiyan, Kevin Frank et al.|JAMA|2015Cited by 416
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial resultsKelly C. Goldsmith, Yaël P. Mossé, Julie R. Park et al.|Nature Medicine|2023Cited by 125
Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating FactorBenjamin Lerman, Rochelle Bagatell, Yimei Li et al.|Journal of Clinical Oncology|2022Cited by 42